EN DE
STOCK COMPARISON

Sandoz Group vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Sandoz Group (SDZ) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees Sandoz Group as the less overvalued of the two: Sandoz Group trades at CHF 69.18 versus a fair value of CHF 44.26 (-36%), while Jiangsu Hengrui Medicine Co trades at ¥52.11 versus ¥25.94 (-50%).
Sandoz Group
SDZ.SW · CHF · Health Care
-36%
upside to fair value
overvalued
PriceCHF 69.18
Fair ValueCHF 44.26
Quality63/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-50%
upside to fair value
overvalued
Price¥52.11
Fair Value¥25.94
Quality59/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Sandoz GroupJiangsu Hengrui Medicine Co
Valuation
38.3×P/E (TTM)43.6×
3.10×P/S (TTM)10.84×
3.69×P/B5.76×
19.9×EV/EBITDA33.0×
0.86×PEG0.93×
1.6%Dividend yield0.4%
CHF 1.01Dividend per share¥0.20
Profitability
8%Net margin25%
14%Operating margin32%
10%Return on equity15%
4%Return on assets9%
Growth
11%Revenue growth (YoY)13%
9.4%Avg. growth/yr (3Y)13.9%
6.3%Avg. growth/yr (5Y)2.5%
Balance & size
0.50×Debt / equity—
$35BMarket cap$52B
healthyGrowth qualityhealthy

Sandoz Group leads: 7 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Sandoz Groupof which business quality 55 · market factors 75 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 42
ProfitabilityMargins and returns on capital today
40
63
Quality GrowthAre margins and returns improving?
85
41
CashflowEarnings quality: real cash, not paper profit
49
82
Fin. StrengthBalance sheet, leverage, solvency risk
59
100
InvestmentDisciplined investing over empire-building
25
27
Low VolatilityCalm price path (market factor)
82
78
MomentumPrice trend over the last 3–12 months (market factor)
66
30
52W MomentumDistance to the 52-week high (market factor)
84
23
Net IssuanceBuybacks instead of dilution
76
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Sandoz Group

DCF ModelsCHF 43.62
Earnings-BasedCHF 26.97
Dividend DiscountCHF 12.81
MultiplesCHF 45.55
Asset-BasedCHF 14.53
Growth DCFCHF 41.57
Economic ProfitCHF 30.25
Growth EarningsCHF 37.76

26 of 26 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.11
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥22.37
Asset-Based¥6.44
Growth DCF¥38.47
Economic Profit¥18.21
Growth Earnings¥29.68

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Sandoz Group
Bear CHF 26.97Fair Value CHF 44.26Bull CHF 55.32
CHF 69.18 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥52.11 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Sandoz Group · Health Care

Quality score63 · Top 25%
Fair value upside-36% · below median

Jiangsu Hengrui Medicine Co · Health Care

Quality score59 · Top 25%
Fair value upside-50% · below median

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees Sandoz Group as the less overvalued of the two: Sandoz Group trades at CHF 69.18 versus a fair value of CHF 44.26 (-36%), while Jiangsu Hengrui Medicine Co trades at ¥52.11 versus ¥25.94 (-50%).

Sandoz Group has the higher quality score (63/100).

See the full analysis →
Sandoz Group · Jiangsu Hengrui Medicine Co

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Sandoz Group

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Jiangsu Hengrui Medicine Co

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.